What is new in the management of Helicobacter pylori?
Since the discovery of Helicobacter pylori in the early 1980s several treatment regimens have been developed to effectively treat this infection. International guidelines have allowed consensus on the best management and improved eradication rates. In recent years increasing antimicrobial resistance and falling eradication rates highlight the need for updated guidelines. In this article we review the most recent European management guidelines and in view of the unavailability of some drugs consider new treatment regimens for the management of H. pylori in Ireland.
Egan
B J
BJ
Department of Clinical Medicine, Adelaide and Meath Hospital incorporating National Children's Hospital Tallaght, Trinity College Dublin, Tallaght, Dublin, Ireland. eganbr@tcd.ie
O'Connor
H J
HJ
O'Morain
C A
CA
D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D009853:Omeprazole / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D019936:Probiotics / Q000627:therapeutic use; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D017828:Rifabutin / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D008795:Metronidazole; D017828:Rifabutin; D000658:Amoxicillin; D013752:Tetracycline; D017291:Clarithromycin; D009853:Omeprazole